Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
出版年份 2020 全文链接
标题
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
作者
关键词
Wilms tumour, Relapse, High-risk, Trial, Phase I/II, Organoids, SIOP-RTSG, COG, ITCC
出版物
EUROPEAN JOURNAL OF CANCER
Volume 144, Issue -, Pages 113-122
出版商
Elsevier BV
发表日期
2020-12-18
DOI
10.1016/j.ejca.2020.11.012
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study
- (2020) Najat C. Daw et al. JOURNAL OF CLINICAL ONCOLOGY
- An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
- (2020) Camilla Calandrini et al. Nature Communications
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study
- (2019) Amy B. Hont et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation
- (2019) F. Spreafico et al. BONE MARROW TRANSPLANTATION
- Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report
- (2019) David B. Dix et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- Novel therapy for pediatric and adolescent kidney cancer
- (2019) Amy L. Walz et al. CANCER AND METASTASIS REVIEWS
- Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor
- (2019) Andrew J. Murphy et al. Nature Communications
- A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
- (2018) Paul J. Wood et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I results of a phase I/II study of weekly nab -paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
- (2018) Lucas Moreno et al. EUROPEAN JOURNAL OF CANCER
- A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system
- (2018) Peter E. Manley et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
- (2018) Meredith K. Chuk et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
- (2018) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)
- (2018) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
- (2018) James I. Geller et al. CANCER
- Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?
- (2017) Jesper Brok et al. EUROPEAN JOURNAL OF CANCER
- A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
- (2017) Samantha Gadd et al. NATURE GENETICS
- Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol
- (2017) Marry M. van den Heuvel-Eibrink et al. Nature Reviews Urology
- Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group
- (2017) Janna A. Hol et al. PEDIATRIC BLOOD & CANCER
- Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
- (2017) Shakeel Modak et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
- (2017) James I. Geller et al. PEDIATRIC BLOOD & CANCER
- Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics
- (2017) Roya Tabatabai et al. Targeted Oncology
- Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
- (2017) Nobuhiro Tsuchiya et al. OncoImmunology
- A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
- (2017) Oren J. Becher et al. PLoS One
- Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
- (2016) Ariadne H.A.G. Ooms et al. CLINICAL CANCER RESEARCH
- Biology and treatment of renal tumours in childhood
- (2016) Jesper Brok et al. EUROPEAN JOURNAL OF CANCER
- Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis
- (2016) Li-Wei Yap et al. Fetal and Pediatric Pathology
- Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study
- (2016) Tasnim Chagtai et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group
- (2016) Eric J. Gratias et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
- (2016) Andrew D.J. Pearson et al. Oncotarget
- Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences
- (2016) Filippo Spreafico et al. Oncotarget
- Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications
- (2016) George D. Cresswell et al. EBioMedicine
- Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors
- (2015) Amy L. Walz et al. CANCER CELL
- Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration
- (2015) Jeffrey S. Dome et al. JOURNAL OF CLINICAL ONCOLOGY
- Stratification of Wilms tumor by genetic and epigenetic analysis
- (2015) Richard H. Scott et al. Oncotarget
- Wilms’ tumor geneWT1promotes homologous recombination-mediated DNA damage repair
- (2014) Yusuke Oji et al. MOLECULAR CARCINOGENESIS
- Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG)
- (2014) A. M. C. Mavinkurve-Groothuis et al. PEDIATRIC BLOOD & CANCER
- TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
- (2014) Mariana Maschietto et al. PLoS One
- Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab
- (2013) Rajkumar Venkatramani et al. PEDIATRIC BLOOD & CANCER
- Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients
- (2012) H. Segers et al. EUROPEAN JOURNAL OF CANCER
- An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour
- (2012) Tam C. Ha et al. EUROPEAN JOURNAL OF CANCER
- Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse
- (2012) Daniela Perotti et al. GENES CHROMOSOMES & CANCER
- Treatment of relapsed Wilms tumors: lessons learned
- (2009) Filippo Spreafico et al. Expert Review of Anticancer Therapy
- Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group
- (2007) Marcio Malogolowkin et al. PEDIATRIC BLOOD & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation